IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD)patients leads to improved metabolic control as measured by the magnitude of change from the baseline value in the HbA1c levels.

Secondary Objectives: To demonstrate that use of glucose-sparing PD solutions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) CAPD and APD patients leads to lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic events requiring medical intervention, improved metabolic control, nutritional status, and Quality of Life. In a subgroup of patients, the impact of glucose-sparing PD solutions (PEN vs Dianeal only) on abdominal fat and left ventricular (LV) structure and function will be assessed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baxter Healthcare Corporation
• Treatments: Icodextrin

Criteria

Inclusion Criteria:

1. M/F patients 18 years of age or older

2. Diagnosis of ESRD (GFR ≤ 15 mL/min)

3. CAPD or APD using only Dianealand/or Physioneal, at least 1 exchange of 2.5% or 4.25% dextrose/day, no prescribed dry time

4. DM (Type 1 and 2) on glycemic-control medication, for 90 days

5. HbA1c > 6.0% but ≤ 12.0%

6. Blood hemoglobin ≥ 8.0 g/dL, but ≤ 13.0 g/dL

Exclusion Criteria:

1. Cardiovascular event within the last 90 days

2. Ongoing clinically significant congestive heart failure (NYHA class III or IV)

3. Allergy to starch-based polymers

4. Glycogen storage disease

5. Maltose, or isomaltose intolerance

6. Peritonitis, exit-site or tunnel infection treated with antibiotics within last 30 days

7. Mean Arterial Pressure (MAP) ≥ 125 mm Hg, or volume depleted (MAP < 77) at Screening.

8. Serum urea > 30 mmol/L

9. Exposure to Extraneal or Nutrineal within the last 60 days prior to Screening visit, Day 1.

10. Receiving rosiglitazone maleate